Boston Scientific (BSX) Total Debt (2009 - 2026)

Boston Scientific (BSX) has 18 years of Total Debt data on file, last reported at $11.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Debt fell 2.48% year-over-year to $11.0 billion; the trailing twelve-month figure through Mar 2026 stood at $11.0 billion (down 2.48% YoY), and the FY2025 full-year result was $11.4 billion, up 6.42% from the prior year.
• Total Debt declined to $11.0 billion in Q1 2026, from $11.4 billion in the prior quarter.
• In the past five years, Total Debt ranged from a high of $11.6 billion in Q3 2025 to a low of $980.0 million in Q2 2025.
• A 5-year average of $8.8 billion and a median of $9.1 billion in 2023 frame the typical range for Total Debt.
• Across the five-year window, Total Debt jumped 176.24% in 2023 and slumped 90.73% in 2025, its largest moves.
• Tracing BSX's Total Debt over 5 years: stood at $3.3 billion in 2022, then soared by 176.24% to $9.1 billion in 2023, then gained by 18.06% to $10.7 billion in 2024, then advanced by 6.42% to $11.4 billion in 2025, then fell by 3.56% to $11.0 billion in 2026.
• Business Quant data shows BSX's Total Debt at $11.0 billion in Q1 2026, $11.4 billion in Q4 2025, and $11.6 billion in Q3 2025.